ReviewTropical medicine and infectious disease2023
Systematic Review of Treatment Failure and Clinical Relapses in Leishmaniasis from a Multifactorial Perspective: Clinical Aspects, Factors Associated with the Parasite and Host.
Review in Tropical medicine and infectious disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Antileishmanial Activity of Bioactive Compounds Obtained fromMolecules (Basel, Switzerland) · 2026Pooled it
- Development of a predictive model for meglumine antimoniate treatment failure in patients with cutaneous leishmaniasis: Aretrospective cohort study.PLoS neglected tropical diseases · 2026Article
- Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases.Drug delivery and translational research · 2026Review
- Plants with promising antileishmanial activity in Colombia: A systematic review and meta-analysis.Parasite epidemiology and control · 2026Review
- Evidence Gaps and Global Patterns in Leishmaniasis Control: A Scoping Review of Clinical, Diagnostic, and Treatment Strategies.Journal of parasitology research · 2026Review
- Clinical, laboratory, and therapeutic characteristics of cutaneous leishmaniasis: 15-year incidence in Crete and Greece, and implications for clinician awareness.GMS hygiene and infection control · 2026Article
- Diagnostic methods for protozoan diseases: a review focused on leishmaniasis, Chagas disease and malaria.Frontiers in microbiology · 2026Review
- Insights into drug resistance inADMET & DMPK · 2026Review
- Unveiling prognostic indicators in canine leishmaniosis: two decades of evidence.Parasites & vectors · 2025Article
- A Review on Phytochemistry, Ethnopharmacology, and Antiparasitic Potential ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Interplay of human macrophage response and natural resistance of infection by L. (V.) panamensis to pentavalent antimony.PLoS neglected tropical diseases · 2025Article
- Circulating Soluble Factors and T-Cell Subsets as Immunological Predictors of Therapy Response in Human Cutaneous Leishmaniasis.The Journal of infectious diseases · 2025Article
- Persistence ofBiomedicines · 2025Article
- Relationship Between Hepcidin, Iron Metabolism, Inflammation and Hypersplenism in Anaemia of Kala-Azar.Parasite immunology · 2025Article
- Bioactive Compounds with Leishmanicidal Potential fromMolecules (Basel, Switzerland) · 2025Article
- The Impact of Anthropic and Natural Events on Leishmaniasis Burden, Control Measures, and Public Health Importance.Transboundary and emerging diseases · 2025Review
- Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies.Frontiers in molecular biosciences · 2025Review
- Caspase-1 Variants and Plasma IL-1β in Patients withInternational journal of molecular sciences · 2024Article
- Complicated Mucocutaneous Leishmaniasis With Superimposed Cellulitis in an Immunocompromised Patient: A Case Report.Cureus · 2024Article
- Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Leishmaniasis is a disease caused by protozoa of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.